Healthcare Review: Obagi Medical Products, Sucampo Pharmaceuticals, Repligen Corporation, Tenet Healthcare Corp, Albany Molecular Research Print E-mail
By Staff and Wire Reports   
Wednesday, 03 April 2013 13:09
Stocks fell on Wall Street Wednesday after weak reports on hiring and growth at service companies dampened the outlook for the U.S. economy. U.S. service companies kept growing at a solid pace in March, but the expansion was less than economists were expecting. The Institute for Supply Management's index of service companies fell to 54.4 from 56 a month earlier. The report was the weakest in seven months and fell short of what analysts were expecting.

Following are notable movers at mid day on Wednesday:

Obagi Medical Products, Inc. (NASDAQ:OMPI) shares increased 9.64% to $25.08. The company today announced that Obagi and Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) have executed an amendment to their Agreement and Plan of Merger, dated March 19, 2013. The expiration date of the tender offer will remain 12:00 midnight, New York City time, on April 23, 2013.

Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) shares grew 7.27% to $6.79. The company announced that it will webcast its corporate presentation at the 20th Annual Future Leaders in the Biotech Industry Conference on Friday, April 5 at 3:00 pm Eastern.

Additionally, analysts at Cantor Fitzgerald initiated coverage on shares of Sucampo Pharmaceuticals in a research report issued to clients and investors on April 3. The firm set a “buy” rating and a $9.00 price target on the stock.

Repligen Corporation (NASDAQ:RGEN) shares climbed 3.63% to $7.33. The Company, on March 7, reported total revenue for the three-month period ended December 31, 2012 of $18,814,000, an increase of $11,649,000 as compared to total revenue of $7,165,000 for the same period in 2011. Operating expenses for the three-month period ended December 31, 2012 were $12,403,000 compared to $8,703,000 for the same period in 2011, an increase of $3,700,000 or 43%.

Tenet Healthcare Corp. (NYSE:THC) shares declined 5.54% to $45.16. THC‘s stock had its “overweight” rating restated by equities researchers at JPMorgan Chase in a report issued on Mar. 25. They currently have a $55.00 target price on the stock, up from their previous target price of $41.00.

Additionally, the company posted its quarterly earnings results on February 26. The company reported $0.45 earnings per share for the quarter, missing the analysts’ consensus estimate of $0.68 by $0.23. The company had revenue of $2.33 billion for the quarter, compared to the consensus estimate of $2.34 billion.

Albany Molecular Research, Inc. (NASDAQ:AMRI) shares fell 5.27% to $9.70. AMRI’s stock had its price target lifted by Sterne Agee from $8.50 to $12.00 in a research report sent to investors on Mar. 8. The firm currently has a buy rating on the stock.

Additionally, the company released its earnings data on Tuesday, February 12th. The company reported $0.17 EPS for the quarter, beating the consensus estimate of $0.09 by $0.08. The company had revenue of $59.10 million for the quarter, compared to the consensus estimate of $56.49 million.




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter